Advanced thyroid cancer
Most types of thyroid cancer are highly treatable. However, sometimes the usual therapies may no longer work. Until recently, the options for treating advanced thyroid cancer were limited. Now, however, there is a new class of targeted therapies emerging. These include multikinase inhibitors (MKIs).
The Thyroid Cancer Alliance has produced a consensus document to guide patient organisations and clinicians on providing information and support for patients with advanced thyroid cancer. This is one of the outcomes of a unique patient-led workshop held in Paris in October 2014 and moderated by Clive Harmer and Fausto Palazzo.
Signatories
Perea, Soledad R., ACTIRA, Buenos Aires,Argentina
Armstrong, Nicola, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Bartès, Beate, Vivre sans Thyroide, Paris, France
Brose, Marcia S., Otorhinolaryngology: Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, United States
Elisai, Rossella, University of Pisa, Pisa, Italy
Farnell, Kate, Butterfly Thyroid Cancer Trust, Newcastle, United Kingdom
Grey, Joanna, Association for Multiple Endocrine Neoplasm Disorders, Tunbridge Wells, United Kingdom
Harmer, Clive, Clinical Oncologist, London, United Kingdom
Hobrough, Helen, Thyroid Cancer Support Group Wales, Cardiff, United Kingdom
Luster, Markus, University of Marburg, Marburg, Germany
Mallick, Ujjal, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
McGarry, Mary, Thyroid Cancer Support Group Ireland, Dublin, Ireland
Moss, Laura, Velindre Cancer Centre, Cardiff, United Kingdom
Palazzo, Fausto, Hammersmith Hospital & Imperial College, London, United Kingdom
Porrey, Marika, Schildklier Organisaties Nederland (SON), Amersfoort, Netherlands
Pitoia, Fabian A., Hospital de Clínicas – University of Buenos Aires, Buenos Aires, Argentina
Schlumberger, Martin, Centre de Lutte Contre le Cancer (CLCC) de Villejuif, Institut Gustave Roussy, Villejuif, France
Carmen Villar, AECAT, Madrid, Spain
Taylor, Judith, Thyroid Cancer Alliance, Diss, Norfolk, United Kingdom
In October 2015 the consensus document and patient information leaflets were presented during a TCA-led symposium during the International Thyroid Congress in Florida. These documents have now been translated into Spanish, French, and German and are available here:
Patient information and stories
Consensus document
Information and support for patients on treatment with multikinase inhibitors (MKIs) – guidance for physicians and patient organisations.
Information et soutien aux patients concernés par un traitement par des inhibiteurs multikinasesrecommandations destinées aux médecins et aux associations.
Información y apoyo para pacientes en tratamiento con inhibidores multiKinasas (multikinase inhibitors, MKI) una guía para facultativos y organizaciones de pacientes.
Information und Unterstützung für Patienten bei der Behandlung mit Multikinase-Inhibitoren (MKIs) – eines Leitfadens für Ärzte und Patientenorganisationen.
Advanced differentiated thyroid cancer (DTC)
Multikinase inhibitors (MKIs): Information for patients with advanced differentiated thyroid cancer.
Inhibiteurs multikinases : Informations destinées aux patients atteints d’un cancer différencié de la thyroïde à un stade avancé
Inhibidores multicinasa (multikinase inhibitors, MKI): Información para pacientes con cáncer de tiroides diferenciado avanzado.
Multikinase-Inhibitoren (MKIs): Informationen für Patienten mit fortgeschrittenem differenziertem Schilddrüsen-Karzinom.
Advanced medullary thyroid cancer (MTC)
Multikinase inhibitors (MKIs): Information for patients with advanced medullary thyroid cancer.
Inhibiteurs multikinases : Informations destinées aux patients atteints d’un cancer médullaire de la thyroïde à un stade avancé.
Inhibidores multikinasas (multikinase inhibitors, MKI): Información para pacientes con cancer medular de tiroides avanzado.
Multikinase-Inhibitoren (MKIs): Informationen für Patienten mit fortgeschrittenem medullärem Schilddrüsen-Karzinom.